Castle Biosciences Data Validates DecisionDx-Melanoma for SLNB Decision-Making
Event summary
- Castle Biosciences presented late-breaking data at EADV 2026 showing DecisionDx-Melanoma can identify low-risk patients who may safely forgo sentinel lymph node biopsy (SLNB).
- Study of 2,799 patients across 29 U.S. centers found 5-year recurrence-free survival (RFS) of 99.6% for low-risk patients who avoided SLNB.
- Test also stratified recurrence risk beyond traditional staging, with high-risk Class 2B results in early-stage patients showing RFS similar to stage IIB disease.
The big picture
The data reinforces the growing trend of molecular diagnostics enhancing traditional staging methods in oncology. Castle Biosciences is positioning DecisionDx-Melanoma as a key tool in personalized melanoma treatment, potentially reducing unnecessary procedures while improving outcomes for high-risk patients. The findings come at a time when precision medicine is gaining traction across cancer care, with payers increasingly valuing tests that demonstrate clear clinical utility and cost-effectiveness.
What we're watching
- Clinical Adoption
- How quickly dermatologists and oncologists will integrate these findings into treatment protocols for melanoma patients.
- Regulatory Impact
- Whether these data will support expanded indications or reimbursement coverage for DecisionDx-Melanoma.
- Competitive Positioning
- The pace at which Castle Biosciences can leverage this validation to differentiate itself in the growing molecular diagnostics market.
Related topics